CAMBRIDGE, Mass.--(BUSINESS WIRE)--Moderna, Inc., (Nasdaq: MRNA) a clinical stage biotechnology company pioneering messenger RNA (mRNA) therapeutics and vaccines to create a new generation of transformative medicines for patients, today announced that Tracey Franklin has been appointed Chief Human Resources Officer. She will serve on Moderna’s Executive Committee, reporting to Chief Executive Officer Stéphane Bancel.
“We are excited to welcome Tracey to Moderna as we continue making progress across our pipeline and prepare to advance additional investigational mRNA medicines into Phase 2 clinical trials,” said Stéphane Bancel, CEO. “Her track record at Merck of delivering human resources strategies to enable high-performing research, development, manufacturing and commercial teams globally will be instrumental as we continue to grow as a biotech company, advance our pipeline and build late-stage development and commercial capabilities that will be essential to our future growth. Tracey has the experience of operating at scale and across geographies in a science-driven pharmaceutical company and will be a great partner to ensure we maintain the uniqueness of our culture.”
Ms. Franklin will join Moderna in October 2019 following 15 years at Merck & Co., Inc. Most recently, she led Merck’s global talent strategy as Vice President, HR Chief Talent and Strategy Officer. In this role Tracey was responsible for leading the vision, development and execution of the company’s Talent and Workforce Strategy with a focus on evolving the organizational culture and talent for the future. Previous leadership roles included responsibility for HR for all divisions in the European region, head of HR for the U.K. and Ireland subsidiaries of Merck, and HR Operations leader responsible for HR program implementation across Merck’s global footprint. In these various leadership roles, she was based in Switzerland, the U.K. and the U.S. and served on Merck’s HR Leadership Team.
“I am thrilled to be joining the Moderna team at such an important time as they move this unique science and technology forward to change the course of healthcare for patients and society. I have spent time with the talented leaders at the company and I am thoroughly impressed by the sophistication, pace and breadth of the organization,” said Ms. Franklin. “I look forward to building upon the good work done to date and continuing to advance the company’s organizational and talent strategies to ensure we are best positioned as we grow to have the highest impact on patients across the globe.”
Ms. Franklin holds a bachelor’s in communication arts and sciences from Pennsylvania State University and a master’s in industrial and organizational psychology from Fairleigh Dickinson University.
Moderna is advancing messenger RNA (mRNA) science to create a new class of transformative medicines for patients. mRNA medicines are designed to direct the body’s cells to produce intracellular, membrane or secreted proteins that can have a therapeutic or preventive benefit and have the potential to address a broad spectrum of diseases. Moderna’s platform builds on continuous advances in basic and applied mRNA science, delivery technology and manufacturing, providing the Company the capability to pursue in parallel a robust pipeline of new development candidates. Moderna is developing therapeutics and vaccines for infectious diseases, immuno-oncology, rare diseases and cardiovascular diseases, independently and with strategic collaborators.
Headquartered in Cambridge, Mass., Moderna currently has strategic alliances for development programs with AstraZeneca, Plc. and Merck, Inc., as well as the Defense Advanced Research Projects Agency (DARPA), an agency of the U.S. Department of Defense; the Biomedical Advanced Research and Development Authority (BARDA), a division of the Office of the Assistant Secretary for Preparedness and Response (ASPR) within the U.S. Department of Health and Human Services (HHS). Moderna has been ranked in the top ten of Science’s list of top biopharma industry employers for the past four years. To learn more, visit www.modernatx.com.